• Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
  • FDA approval could spark huge interest in Mainz Biomed (NASDAQ:MYNZ)
  • Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission
  • Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance
  • Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
  • Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference
  • Mainz Biomed to Host Key Opinion Leader Event at DDW 2022
  • Mainz Biomed Provides Product Development Update on PancAlert